Matinas BioPharma: Rises as fungal meningitis therapy gets approval for trial

Matinas BioPharma Holdings

19/02/2020 13:36

**  Matinas BioPharma Holdings Inc's  MTNB.K  shares rise
6.2% to $1.4 premarket - set for their best day in more than a
month
    ** Co says the independent Data Safety Monitoring Board has
approved its drug for HIV-patients with a type of fungal
meningitis for the second part of a mid-stage study  urn:newsml:reuters.com:*:nGNX85vm5B
    ** Co's study has two parts- Part 1 was designed to
determine the maximum tolerated dose among HIV patients who do
not have a fungal infection, while Part 2 will assess the
safety, tolerability and efficacy of the drug in HIV-infected
patients with fungal meningitis
    ** Part 2 trial to commence in Q1 2020- MTNB
    ** Up to Tuesday's close, stock had risen 25% in the last 12
months

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))